Brief: AstraZeneca Says CHMP Recommends Datroway For Approval In EU As 1st-Line Treatment For Metastatic TNBC
29/06/2026 07:52
BRIEF-AstraZeneca Says CHMP Recommends Datroway For Approval In EU As 1st-Line Treatment For Metastatic TNBC June 29 (Reuters) - AstraZeneca PLC AZN.L:
ASTRAZENECA PLC - DATROWAY RECOMMENDED FOR APPROVAL IN EU FOR TNBC
ASTRAZENECA - CHMP RECOMMENDS DATROWAY FOR APPROVAL IN EU AS 1ST-LINE TREATMENT FOR METASTATIC TNBC
Source text: ID:nRSc0134Ka
Further company coverage: AZN.L
(((( Reuters.Briefs@thomsonreuters.com ;));))
Recent news on AstraZeneca
See all newsUK Stocks-Factors to watch on July 10 (updated)
UK Stocks-Factors to watch on July 10
US appeals court upholds win for AstraZeneca in Pfizer cancer drug patent fight (updated)
US appeals court upholds win for AstraZeneca in Pfizer cancer drug patent fight
UK's FTSE 100 ticks lower as AstraZeneca drag offsets banks, mining gains